معرفی
Claire Lancaster is an Assistant Professor in Dementia (Clinical Neuroscience) at Brighton and Sussex Medical School, University of Sussex. She is actively engaged in research focused on the genetic and cognitive underpinnings of Alzheimer’s Disease, particularly the impact of the APOE ε4 gene variant across the lifespan.
Education:
- PhD in Experimental Psychology, University of Sussex (2014–2017)
- MSc in Cognitive Neuroscience, University College London (2013–2014)
- BSc in Experimental Psychology, University of Bristol (2010–2013)
Her research lies at the intersection of genetics, cognitive neuroscience, and digital health, with a strong emphasis on early detection of neurodegenerative diseases. She investigates how APOE ε4 affects cognition, brain structure, and function, and explores pharmacological and lifestyle interventions to mitigate risk. Her work integrates neuroimaging, digital biomarkers (e.g., Mezurio app), and cognitive testing to identify preclinical markers of dementia.
The analysis of her recent publications reveals a consistent focus on APOE-related cognitive changes, digital tools for remote monitoring, and early intervention strategies. Her work spans clinical populations and healthy at-risk individuals, often involving collaborations with NHS, charities, and industry partners. She has contributed to major initiatives such as the Early Detection of Neurodegenerative diseases (EDoN) and RADAR-AD studies.
Scientific Awards:
- Alzheimer's Society Fellowship
Dr. Lancaster has secured significant research funding from Alzheimer's Research UK and the Alzheimer's Society, supporting projects on hippocampal hyperactivity, verbal fluency metrics, and digital cognitive assessment. She collaborates with multidisciplinary teams and mentors early-career researchers, though formal student advisees are not listed. Her work is instrumental in advancing the use of digital technologies for dementia risk assessment and early detection.
Labs and Research Teams:
She is involved in the EDoN initiative and the RADAR-AD study, and her research group focuses on digital biomarkers and cognitive neuroscience in dementia risk. She collaborates with NHS providers, technology companies, and charity organizations to translate research into clinical applications.
